A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib
Crossref DOI link: https://doi.org/10.1007/s00280-016-3020-z
Published Online: 2016-05-06
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Malhi, Vikram
Colburn, Dawn
Williams, Sarah J.
Hop, Cornelis E. C. A.
Dresser, Mark J.
Chandra, Priya
Graham, Richard A.
Funding for this research was provided by:
F. Hoffmann-La Roche, Ltd.
License valid from 2016-05-06